You just read:

Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress

News provided by

Ryvu Therapeutics

May 14, 2020, 09:30 ET